tradingkey.logo

AxoGen Inc

AXGN

17.260USD

+0.440+2.62%
Close 09/18, 16:00ETQuotes delayed by 15 min
789.91MMarket Cap
LossP/E TTM

AxoGen Inc

17.260

+0.440+2.62%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
12 / 207
Overall Ranking
64 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
24.875
Target Price
+47.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.18% year-on-year.
Undervalued
The company’s latest PE is -173.12, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.91M shares, decreasing 5.32% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.72M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.01.

Financial Health

Currency: USD Updated2025-09-18

The company's current financial score is 8.96, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 56.66M, representing a year-over-year increase of 18.26%, while its net profit experienced a year-over-year increase of 130.14%.

Score

Industry at a Glance

Previous score
8.96
Change
0

Financials

7.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.72

Company Valuation

Currency: USD Updated2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -168.71, which is -91.11% below the recent high of -15.00 and 75.78% above the recent low of -40.86.

Score

Industry at a Glance

Previous score
1.20
Change
1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-18

The company’s current earnings forecast score is 8.50, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for AxoGen Inc is 25.50, with a high of 30.00 and a low of 20.00.

Score

Industry at a Glance

Previous score
8.50
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts
Buy
Current Rating
24.875
Target Price
+47.89%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
AxoGen Inc
AXGN
8
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-18

The company’s current price momentum score is 9.24, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 18.08 and the support level at 14.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.24
Change
0.14

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-0.007
Neutral
RSI(14)
67.282
Neutral
STOCH(KDJ)(9,3,3)
87.360
Overbought
ATR(14)
0.587
High Vlolatility
CCI(14)
157.833
Buy
Williams %R
3.349
Overbought
TRIX(12,20)
0.597
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
16.718
Buy
MA10
16.490
Buy
MA20
16.161
Buy
MA50
14.446
Buy
MA100
13.107
Buy
MA200
15.095
Buy

Institutional Confidence

Currency: USD Updated2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 91.08%, representing a quarter-over-quarter decrease of 1.49%. The largest institutional shareholder is The Vanguard, holding a total of 2.72M shares, representing 5.92% of shares outstanding, with 7.65% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
First Light Asset Management, LLC
4.47M
-0.72%
BlackRock Institutional Trust Company, N.A.
3.13M
+3.07%
The Vanguard Group, Inc.
Star Investors
2.53M
+4.28%
Morgan Stanley & Co. LLC
1.59M
-6.24%
Balyasny Asset Management LP
680.19K
+126.77%
ArrowMark Colorado Holdings, LLC
1.59M
-29.25%
Soleus Capital Management, L.P.
1.45M
-51.08%
Wasatch Global Investors Inc
Star Investors
774.63K
--
Zaderej (Karen L)
1.14M
+6.62%
State Street Global Advisors (US)
1.01M
+5.08%
1
2

Risk Assessment

Currency: USD Updated2025-09-18

The company’s current risk assessment score is 3.22, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.22
Change
0
Beta vs S&P 500 index
1.03
VaR
+5.57%
240-Day Maximum Drawdown
+53.80%
240-Day Volatility
+71.22%
Return
Best Daily Return
60 days
+9.60%
120 days
+9.60%
5 years
+36.90%
Worst Daily Return
60 days
-9.04%
120 days
-23.18%
5 years
-23.18%
Sharpe Ratio
60 days
+4.84
120 days
-0.10
5 years
+0.33
Risk Assessment
Maximum Drawdown
240 days
+53.80%
3 years
+72.42%
5 years
+84.64%
Return-to-Drawdown Ratio
240 days
+0.33
3 years
+0.23
5 years
+0.00
Skewness
240 days
-0.45
3 years
+1.94
5 years
+1.39
Volatility
Realised Volatility
240 days
+71.22%
5 years
+66.84%
Standardised True Range
240 days
+4.89%
5 years
+3.87%
Downside Risk-Adjusted Return
120 days
-11.53%
240 days
-11.53%
Maximum Daily Upside Volatility
60 days
+54.34%
Maximum Daily Downside Volatility
60 days
+36.55%
Liquidity
Average Turnover Rate
60 days
+2.82%
120 days
+2.04%
5 years
--
Turnover Deviation
20 days
+201.03%
60 days
+124.18%
120 days
+62.69%

Peer Comparison

Healthcare Equipment & Supplies
AxoGen Inc
AxoGen Inc
AXGN
7.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.20 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.09 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.94 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI